Beschreibung:
<jats:title>Abstract</jats:title><jats:p>Lower-grade gliomas (LGGs), which are uniformly fatal in young adults, are classified as grades II-III tumors according to their histological features. The NFκB transcription factor, a crucial player in cancer initiation and progression, is inactivated in the cytoplasm by inhibitory proteins (IκBs) that have been shown to exert tumor-suppressor activity. Therefore, using The Cancer Genome Atlas copy number alteration and RNA-Seq data from 398 patients, we evaluated the association between the expression and dosage of <jats:italic>NFKBIA</jats:italic>, which encodes IκBα, and the overall malignancy of LGGs. Deletion and low expression of <jats:italic>NFKBIA</jats:italic> were associated with enhanced tumor aggressiveness and poor prognosis in LGGs. Accordingly, the dosage and expression of <jats:italic>NFKBIA</jats:italic> were independent prognostic factors for 5-year survival (dosage: <jats:italic>P</jats:italic> = 0.016; expression: <jats:italic>P</jats:italic> = 0.002) and 5-year recurrence-free survival (dosage: <jats:italic>P</jats:italic> = 0.009; expression: <jats:italic>P</jats:italic> = 0.005). Moreover, gene set enrichment analyses and co-expression network analyses indicated a role for <jats:italic>NFKBIA</jats:italic> in the negative regulation of cell proliferation, possibly through the modulation of downstream NFκB activation. Overall, the present findings reveal the prognostic value of <jats:italic>NFKBIA</jats:italic> in LGGs, reinforcing the relevance of NFκB signaling in the development and progression of gliomas.</jats:p>